Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $660.5 million, a decrease of 5.2% year-over-year, primarily due to lower pass-through costs in clinical pharmacology and clinical development businesses [24] - Full year 2025 revenue was $2,723.4 million, reflecting a 1% increase year-over-year, driven mainly by higher revenue in the clinical pharmacology business [25] - Adjusted EBITDA for the fourth quarter was $54 million, down from $56 million in the prior year, while full year adjusted EBITDA was $189.9 million, towards the higher end of guidance [27][28] - The company achieved gross savings of approximately $153 million and net savings of $93 million for the year, exceeding original targets [24] Business Line Data and Key Metrics Changes - The clinical pharmacology business saw increased revenue, contributing to the overall revenue growth, while FSP revenue continued to face headwinds [25] - The company secured significant new and repeat wins in Q4, including a long-term clinical pharmacology partnership with a top 5 large pharma company [11] Market Data and Key Metrics Changes - The macro environment showed signs of stabilization and early recovery, with funding activity rebounding significantly in the second half of 2025, particularly in Q4 [9] - Client engagement levels increased, with shorter decision-making timelines and more constructive conversations, especially within biotech [9][43] Company Strategy and Development Direction - The company focuses on disciplined execution and positioning itself to benefit from recovering demand, emphasizing commercial, operational, and financial excellence as its growth pillars [10][22] - The strategy includes expanding client relationships, enhancing operational efficiency, and leveraging technology, particularly AI, to improve service delivery [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about the recovery in the biotech sector, noting improved client engagement and decision-making timelines [42][43] - The company anticipates an uneven recovery in the first half of 2026 but is optimistic about building momentum in the second half as outsourcing trends remain steady [10] Other Important Information - The company paid down approximately $76 million of senior secured notes in Q4, reinforcing its commitment to improving capital structure [24] - The company is targeting full year 2026 revenue in the range of $2.55 billion to $2.65 billion, with adjusted EBITDA expected between $190 million and $220 million [37] Q&A Session Summary Question: Outlook on bookings and market conditions - Management noted that the cautious optimism reflects improvements in client engagement and decision-making timelines, particularly in biotech, with an increase in RFP flow [42][43] Question: Key margin levers and revenue growth - Management indicated that revenue growth is crucial for margin improvement, with expectations for a gradual ramp throughout the year [44][46] Question: Insights on bookings mix and customer engagement - Management confirmed a healthy mix of Phase II and Phase III studies, with a focus on full-service work and improved win rates, particularly in biotech [59][61] Question: Impact of AI on customer conversations - Management emphasized that AI is viewed as a force multiplier that can enhance execution and accelerate pipelines, rather than replacing human roles [104]
Fortrea (FTRE) - 2025 Q4 - Earnings Call Transcript